Relacorilant(Relacorilant) - 药物靶点：GR_在研适应症：库欣综合征，腹膜癌，铂耐药性输卵管癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Relacorilant (USAN)、CORT-125134、CORT125134

靶点

GR

作用方式

拮抗剂

作用机制

GR拮抗剂(糖皮质激素受体拮抗剂)

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病+ [2]

在研适应症

库欣综合征腹膜癌铂耐药性输卵管癌+ [11]

非在研适应症

转移性胰腺导管腺癌三阴性乳腺癌

原研机构

Corcept Therapeutics, Inc.

在研机构

Corcept Therapeutics, Inc.

非在研机构-

权益机构-

最高研发阶段申请上市

首次获批日期-

最高研发阶段(中国)-

特殊审评孤儿药 (美国)、孤儿药 (欧盟)

登录后查看时间轴

结构/序列

分子式C27H22F4N6O3S

InChIKeyWANIDIGFXJFFEL-SANMLTNESA-N

CAS号1496510-51-0

关联

24

项与 Relacorilant 相关的临床试验

NCT06906341

/ Recruiting临床2期

A Phase 2 Study of Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (BELLA)

This is a Phase 2, single-arm, open-label study to evaluate efficacy and safety of intermittent dosing of relacorilant in combination with nab-paclitaxel and bevacizumab in patients with ovarian cancer.

开始日期2025-04-11

申办/合作机构

Corcept Therapeutics, Inc.

NCT05726292

/ Recruiting临床2期IIT

A Randomized Phase II Trial of Neoadjuvant Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy. This study is for individuals who have been diagnosed with advanced, high-risk prostate cancer and standard therapies available to treat your disease have not been effective. Participation in this research will last about 3 years and 9 months.

开始日期2025-01-06

申办/合作机构

The University of Chicago

NCT05257408

/ Active, not recruiting临床3期

A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)

The primary objectives of this study are to evaluate progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS) (evaluated independently, as dual primary endpoints) in patients treated with intermittent regimen of Relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel monotherapy.

开始日期2022-06-29

申办/合作机构

Corcept Therapeutics, Inc.

[+1]

100 项与 Relacorilant 相关的临床结果

登录后查看更多信息

100 项与 Relacorilant 相关的转化医学

登录后查看更多信息

100 项与 Relacorilant 相关的专利（医药）

登录后查看更多信息

36

项与 Relacorilant 相关的文献（医药）

2025-08-01·PHYTOMEDICINE

Tanshinone IIA improved psychological stress-induced embryo implantation disorders by inhibiting GC/GR signaling and promoting angiogenesis

Article

作者: Fang, Qunying ; Zong, Lu ; Han, Hui ; Wang, Jiawei ; Shui, Lijun ; Zhao, Shiyu ; Chen, Shengyuan ; Li, Fangfang ; Meng, Ye ; Jin, Qi ; Wu, Limin ; Qiao, Zonghui

BACKGROUND:

The exact mechanism by which psychological stress leads to embryo implantation disorders remains unclear. Studies have shown that psychological stress is associated with elevated levels of glucocorticoids (GC). Successful embryo implantation is closely related to normal endometrial angiogenesis, a key process in the creation of a conducive environment for embryo implantation. Tanshinone IIA (Tan IIA), a compound derived from traditional Chinese medicine, promotes angiogenesis. This study aimed to elucidate how psychological stress impairs embryo implantation and explore the potential therapeutic effects of Tan IIA.

METHODS:

Female mice were randomly divided into seven groups: control, restraint stress, CORT125134 antagonizing glucocorticoid receptor (GR), 7.5, 15, 30 mg/kg Tan IIA, and aspirin. Open-field and elevated plus maze tests were employed to evaluate behavioral changes. The embryo implantation sites were quantified using trypan blue injection. Endometrial GC levels by ELISA, GR expression by RT-qPCR and WB, angiogenesis by HE and IHC, and angiogenic factors (VEGF, ANG2) by IF were measured. JC-1, ATP, p-DRP1^S616, and transmission electron microscopy were used to detect endometrial mitochondrial damage. Oxidative stress was determined through ROS, MDA, catalase, and GPX4 assays, and IF co-staining of CD31 with 4-HNE examined vascular oxidative injury. Endometrial receptivity was evaluated by LIF and integrin αvβ3 expression.

RESULTS:

Psychological stress significantly induced anxiety-like behavior, reduced implantation sites, impaired endometrial angiogenesis, triggered mitochondrial dysfunction and oxidative stress, and compromised endometrial receptivity via GC/GR signaling activation. Administration of Tan IIA effectively alleviated these stress-induced impairments in a dose-dependent manner, primarily by inhibiting GC/GR activation and GR nuclear translocation. Specifically, Tan IIA alleviated anxiety-like behavior, reduced the p-DRP1^S616/DRP1 ratio, restored MMP and ATP production, and attenuated mitochondrial vacuolization and crista disruption. In addition, Tan IIA markedly decreased the levels of ROS, MDA, and CAT, while enhancing the expression of GPX4, VEGF, ANG2, LIF, and integrin αvβ3.

CONCLUSION:

Psychological stress disrupted embryo implantation by activating the GC/GR signaling. Tan IIA effectively alleviated stress-induced implantation disorders by inhibiting the GC/GR signaling. This study highlights the therapeutic potential of Tan IIA as a promising candidate for stress-related implantation disorders.

2025-06-01·LANCET

Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial

Article

作者: Colombo, Nicoletta ; Diakos, Connie ; McCollum, Michael E ; Artioli, Grazia ; Hopp, Elizabeth ; Garbaos, Gabriel ; Van Gorp, Toon ; De La Cueva, Helena ; Oaknin, Ana ; Mileshkin, Linda ; Monk, Bradley J ; Scandurra, Giuseppa ; Balázs, Boglárka ; Salutari, Vanda ; Kang, Sokbom ; Leiser, Aliza L ; Pai, Sachin G ; Scaranti, Mariana ; Slomovitz, Brian ; Cassani, Chiara ; Devaux, Alix ; Gladieff, Laurence ; Lee, Yong Jae ; O'Malley, David M ; Bagaméri, Andrea ; Vergote, Ignace ; Kaczmarek, Emilie ; Bodnar, Lubomir ; You, Benoit ; Kesner-Hays, Amanda ; Caruso, Giuseppe ; Churruca, Cristina ; de Carvalho Calabrich, Aknar Freire ; Jubb, Adrian M ; Lorusso, Domenica ; Kim, Jae-Weon ; Nicum, Shibani ; McClung, Emily ; Clamp, Andrew ; Olawaiye, Alexander B ; Gilbert, Lucy ; Pashova, Hristina I ; Tudor, Iulia Cristina ; Kim, Byoung-Gie

BACKGROUND:

Relacorilant, a first-in-class selective glucocorticoid receptor antagonist, increases a tumour's sensitivity to chemotherapy by reducing cortisol signalling. This study aimed to show whether the addition of relacorilant to nab-paclitaxel improves progression-free and overall survival in females with platinum-resistant ovarian cancer.

METHODS:

This randomised, controlled, open-label phase 3 trial (ROSELLA [GOG-3073/ENGOT-ov72]) was done at 117 hospitals and community oncology treatment centres in 14 countries across Australia, Europe, Latin America, North America, and South Korea. Patients had to be aged 18 years or older and had to have a confirmed diagnosis of platinum-resistant, epithelial (ie, high-grade serous, endometrioid, or carcinosarcoma with a ≥30% epithelial component) ovarian, primary peritoneal, or fallopian tube cancer; up to three previous lines of anticancer therapy and previous bevacizumab and disease progression or intolerance to the most recent therapy; measurable disease according to the Response Evaluation Criteria in Solid Tumours (RECIST; version 1.1); an Eastern Cooperative Oncology Group performance status of 0 or 1; and adequate organ function. Patients were assigned (1:1) to relacorilant (150 mg orally the day before, of, and after nab-paclitaxel infusion) plus nab-paclitaxel (80 mg/m² intravenously on days 1, 8, and 15 of each 28-day cycle) or nab-paclitaxel monotherapy (100 mg/m² intravenously on the aforementioned schedule). The dual primary endpoints were progression-free survival assessed by blinded independent central review per Response Evaluation Criteria in Solid Tumours (version 1.1) and overall survival, and were assessed in all randomly assigned patients by intention to treat. The safety population included all randomly assigned patients who received at least one dose of the assigned treatment. This trial was registered at ClinicalTrials.gov, NCT05257408, and is ongoing.

FINDINGS:

Between Jan 5, 2023, and April 8, 2024, 381 patients were randomly assigned to the combination group (n=188) or to the nab-paclitaxel monotherapy group (n=193). Patients receiving relacorilant plus nab-paclitaxel had a statistically significant improvement in progression-free survival assessed by blinded independent central review compared with those receiving nab-paclitaxel monotherapy (hazard ratio 0·70 [95% CI 0·54-0·91]; median 6·54 months [95% CI 5·55-7·43] vs 5·52 months [3·94-5·88]; stratified log-rank p=0·0076). At the planned interim analysis, there was a clinically meaningful difference in overall survival with the addition of relacorilant to nab-paclitaxel (0·69 [95% CI 0·52-0·92]; 15·97 months [95% CI 13·47-not reached] vs 11·50 months [10·02-13·57]; log-rank p=0·0121). Adverse events were similar across study groups when adjusted for nab-paclitaxel exposure; no new safety signals were observed.

INTERPRETATION:

The addition of relacorilant to nab-paclitaxel prolonged progression-free survival and interim results also showed an improvement in overall survival. Together, the results position the combination of relacorilant and nab-paclitaxel as a potential new standard treatment for patients with platinum-resistant ovarian cancer.

FUNDING:

Corcept Therapeutics.

2024-11-04·ONCOLOGIST

Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study

Article

作者: Leal, Alexis D ; Skeel, Roland T ; Fountzilas, Christos ; Pashova, Hristina ; Mann, Grace ; Oberstein, Paul E ; Alese, Olatunji B ; Huyck, Timothy K ; Noonan, Anne M ; Kio, Ebenezer A ; Chiorean, Elena Gabriela ; Bahary, Nathan ; Borazanci, Erkut H ; Lee, Valerie ; Chung, Vincent ; Philip, Philip A ; Wainberg, Zev A ; Hanna, Wahid T ; Cardin, Dana B

Abstract:

Background:

Modulation of glucocorticoid receptor (GR) activity in tumor cells enhances chemotherapy efficacy. We evaluated the selective GR modulator relacorilant plus nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who had received at least 2 prior therapy lines.

Patients and Methods:

In this open-label, single-arm, phase III study, patients received once-daily oral relacorilant (100 mg, titrated to 150 mg in 25 mg increments/cycle) and nab-paclitaxel (80 mg/m2) on days 1, 8, and 15 of 28-day cycles. The primary efficacy endpoint was objective response rate (ORR) by blinded independent central review. Progression-free survival (PFS), overall survival (OS), target gene modulation, and safety were also assessed.

Results:

Of 43 patients enrolled, 31 were evaluable for ORR (12 did not reach first postbaseline radiographic assessment). An interim analysis to assess whether ORR was ≥10% showed no confirmed responses and the study was discontinued. Two (6.5%) patients attained unconfirmed partial responses and 15 (48.4%) had stable disease. Fourteen of 31 (45.2%) patients had reductions in target lesion size, despite prior nab-paclitaxel exposure in 12 of the 14. Median PFS and OS were 2.4 months (95% CI, 1.4-4.2) and 3.9 months (95% CI, 2.8-4.9), respectively. The most common adverse events were fatigue and nausea. RNA analysis confirmed that relacorilant plus nab-paclitaxel suppressed 8 cortisol target genes of interest.

Conclusion:

Relacorilant plus nab-paclitaxel showed modest antitumor activity in heavily pretreated patients with mPDAC, with no new safety signals. Studies of this combination in other indications with a high unmet medical need are ongoing.

63

项与 Relacorilant 相关的新闻（医药）

16 小时之前

·ioncology

ESMO妇科癌症大会丨ROSELLA试验：Relacorilant联合白蛋白结合型紫杉醇可延长铂耐药卵巢癌患者的PFS

点击蓝字关注我们根据2025年ESMO妇科癌症大会（维也纳，6月19-21日）上公布的III期ROSELLA试验结果，选择性糖皮质激素受体拮抗剂Relacorilant联合白蛋白结合型紫杉醇（nab-paclitaxel）治疗显著改善了无进展生存期（PFS），即使在预后较差的患者中，联合用药也具有良好的疗效和耐受性（摘要70O）。Domenica Lorusso在2025年ESMO妇科癌症大会上介绍ROSELLA试验的结果III期ROSELLA试验评估了新型选择性糖皮质激素受体拮抗剂Relacorilant与白蛋白结合型紫杉醇联合治疗上皮性卵巢癌、原发性腹膜癌或输卵管癌患者，这些患者在接受最后一剂铂类化疗后6个月内病情进展。381名患者按1:1的比例随机分配接受Relacorilant（150 mg，分别在白蛋白结合型紫杉醇治疗前、治疗当日和治疗后给药）+白蛋白结合型紫杉醇（80 mg/m2，在每个周期[28天]的第1、8和15天给药）。所有患者均需接受过1-3种既往治疗，包括先前的贝伐珠单抗治疗。此外，患者的ECOG体能状态评分（ECOG）需达到0或1分。本试验的主要终点为盲法独立中心审查评估的PFS（根据RECIST 1.1标准）和总生存（OS）。☆根据盲法独立中心审查评估，在原发性铂类药物停药间隔为1-6个月的患者中，Relacorilant组的中位PFS为5.82个月，而单独使用白蛋白结合型紫杉醇组为3.94个月（风险比[HR]=0.70；95%置信区间[CI]0.54-0.91；对数秩检验p=0.0076）；12个月PFS率分别为25% vs 13%。该亚组中接受Relacorilant方案治疗的患者中位OS未达到（NR），而单用白蛋白结合型紫杉醇的患者中位OS为9.56个月（HR=0.52；95% CI: 0.31-0.89；名义P=0.0140）。ROSELLA试验显示，对于铂类耐药性卵巢癌患者，与单用白蛋白结合型紫杉醇相比，Relacorilant联合白蛋白结合型紫杉醇疗法显著改善了患者的PFS（2025年ESMO妇科癌症大会，摘要70O）。☆一项探索性分析显示，在预后特别差的患者亚组中，Relacorilant方案带来一致的获益，其中包括112例首次无铂治疗间期≤6个月的患者（PFS：HR=0.50；95%CI: 0.30-0.84；中期OS：HR=0.52；95%CI: 0.31-0.89）。☆接受Relacorilant联合白蛋白结合型紫杉醇治疗的患者中，74.5%报告了≥3级治疗中出现的不良事件（TEAE），而白蛋白结合型紫杉醇组这一比例为59.5%。当调整联合治疗的较长暴露时间后，两组的安全性概况大致相似，这表明Relacorilant对耐受性的不良影响极小。☆ROSELLA的先前数据：先前在2025年ASCO年会上报告并在ESMO妇科癌症大会上再次分享的数据显示，在总体人群中，Relacorilant联合白蛋白结合型紫杉醇治疗组的中位PFS为6.54个月，而单独使用白蛋白结合型紫杉醇（HR=0.70；P=0.0076）治疗组的中位PFS为5.52个月；两组的中位OS分别为15.97个月和11.50个月，OS改善具有临床意义（HR=0.69；P=0.0121）。ROSELLA试验中期分析显示Relacorilant方案改善OS研究点评美国德克萨斯州休斯顿伍德兰兹的Robert L. Coleman博士在评论疗效数据时表示：“Relacorilant联合白蛋白结合型紫杉醇治疗组12个月时无进展患者比例几乎是白蛋白结合型紫杉醇组的两倍（25% vs 13%）——这是一个非常积极的信号，表明该方案具有疗效。OS数据已成熟约50%，前景光明。”Dr. Coleman强调了该联合用药的合理性：“研究证明，糖皮质激素通路的激活可通过抑制药物诱导的细胞凋亡来降低化疗的疗效。临床前实验和有限的临床数据表明，使用Relacorilant等药物阻断糖皮质激素受体（GR）可以减轻这种效应，从而增强乳腺癌和卵巢癌模型中的细胞毒性（Clin Cancer Res.2009;15:3196–3204）。每周一次的白蛋白结合型紫杉醇给药旨在避免一些常见的紫杉烷类药物的毒性（包括超敏反应和胃肠道症状）——这些不良反应通常需要类固醇预先用药来治疗。这支持了这样的假设：将Relacorilant对糖皮质激素受体的调节与不含类固醇的紫杉烷类药物相结合，可以为卵巢癌患者带来更好的疗效。”虽然跨试验比较存在风险，Dr. Coleman认为MIRASOL、ROSELLA和KEYNOTE-B96试验的结果可以相互结合解读，以确定总体上最有效的方案、治疗顺序以及针对不同卵巢癌亚群的治疗方案。参考文献Lorusso D, et al. Phase III results of relacorilant + nab-paclitaxel vs nab-paclitaxel in platinum-resistant ovarian cancer (PROC) (ROSELLA, GOG-3073, ENGOT-ov72): Secondary endpoints. ESMO Gynaecological Cancers Congress 2025, Abstract 70O（来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床结果ASCO会议临床3期

2025-06-07

·微信

ALS新药错过主要终点，但发现了生存获益

近日，Corcept Therapeutics公司公布了其肌萎缩侧索硬化症（ALS）药物Dazucorilant的Ⅱ期临床DAZALS 12个月的临床数据，相比安慰剂组，Dazucorilant仍然没能减缓患者功能衰退，但显著延长了其总生存期。公司研发总监Bill Guyer表示：公司正与美国和欧洲的监管机构合作，以确定推进Dazucorilant的最佳路径。意外的生存获益？Dazucorilant是Corcept公司开发的一种口服选择性糖皮质激素受体(GR)拮抗剂，通过与GR结合（而不与人体其他激素受体结合）来调节皮质醇活性。此前，Dazucorilant已获FDA授予治疗ALS的快速通道认定和孤儿药资格。DAZALS是一项随机、双盲、安慰剂对照Ⅱ期临床试验，共计入组了249名ALS患者，以1：1：1随机分配接受Dazucorilant（150mg）、Dazucorilant（300mg ）、以及安慰剂的治疗，每日一次，持续24周。该试验6个月的临床数据已在去年12月已经公布，当时，该项试验未能达到主要终点目标，相比安慰剂组，Dazucorilant未能减缓ALS患者功能衰退—ALSFRS-R。随后，Corcept也继续该项临床的扩展研究（开放标签），在该试验满一年后，评估患者的总生存期。根据这次报告的临床数据显示，第6个月时，Dazucorilant（300mg ）无任何患者死亡（0/83），而安慰剂组有5例患者死亡（5/82），Dazucorilant（150mg）有2例患者死亡。生存获益得到了延续，到第12个月时，Dazucorilant（300mg ）组有14名患者死亡，而Dazucorilant（150mg）组有23人死亡，安慰剂组有21人死亡。与安慰剂以及Dazucorilant（150mg）组相比，Dazucorilant（300mg ）组患者表现出更好的总生存期。安全性方面，Dazucorilant显示出可接受的安全性，92%的不良事件的严重程度为轻度至中度，Dazucorilant组出现严重不良事件的频率与安慰剂组患者相似。目前Corcept已经有一款GR拮抗剂Korlym获批，2012年2月获FDA批准用于治疗库欣综合征。此外，公司的另一款GR拮抗剂relacorilant将迎来审批决定，2024年12月30日，Corcept向FDA提交了Relacorilant治疗库欣综合征的新药上市申请（NDA），PDUFA日期定为2025年12月30日。另外，今年3月，Relacorilant与nab-paclitaxel联合用于治疗铂类耐药卵巢癌的Ⅲ期试验ROSELLA达到了主要终点目标，公司计划在2025年第三季度提交新药申请(NDA)。参考出处：https://www.fiercebiotech.com/biotech/corcept-unveils-promising-survival-data-failed-phase-2-als-trialhttps://ir.corcept.com/news-releases/news-release-details/corcept-presents-results-phase-2-study-dazucorilant-patients-0

孤儿药临床3期快速通道临床结果临床2期

2025-06-06

·BioSpace

Corcept Claims Survival Benefit in ALS Despite Missed Endpoint

iStock, cagkansayin Analysts at Truist Securities called the mid-stage data a “mixed bag,” also flagging gastrointestinal adverse events. However, the readout is unlikely to be “incremental” to Corcept’s overall stock narrative. Corcept Therapeutics ’ investigational cortisol modulator dazucorilant failed to boost functional performance in patients with amyotrophic lateral sclerosis—but the biotech dug into the data Thursday and came away with overall survival benefits. Analysts at Truist Securities called the Phase II readout a “mixed bag” in an investor note on Thursday, adding that aside from the missed primary endpoint, dazucorilant also elicited “increased” gastrointestinal adverse events. “We would have liked to see some QoL [quality of life] assessments to better gauge commercial potential as discontinuation rates” seemed higher in the dazucorilant group versus placebo, they said. Still, Truist considered Thursday’s readout to be only “incremental” to Corcept’s overall stock narrative. The analyst firm does not include dazucorilant in its valuation for the biotech. Thursday’s data, presented at the 2025 annual meeting of the European Network to Cure ALS, showed no statistical separation between dazucorilant and placebo patients in terms of scores on the ALS Functional Rating Scale-Revised , a disease-specific severity score that evaluates patients’ disability and respiratory function, among other metrics. However, an exploratory analysis found that dazucorilant treatment significantly improved overall survival. At 24 weeks, five of 82 patients on placebo died, as opposed none of the 83 patients in the dazucorilant arm. At one year, treatment with dazucorilant cut the risk of death by 84% versus placebo. The biotech called this effect “pronounced” in its Thursday release. Given the mixed mid-stage findings, Corcept is currently “working with regulatory authorities” to determine the best path forward for dazucorilant, Bill Guyer, the company’s chief development officer, said in a prepared statement on Thursday. The ALS readout comes after Corcept earlier this week unveiled Phase III data for its selective glucocorticoid receptor antagonist relacorilant, which it combined with nab-paclitaxel to treat patients with platinum-resistant ovarian cancer. The findings, revealed in a late-breaking presentation at the recently concluded 2025 conference of the American Society of Clinical Oncology, showed that the relacorilant regimen cut the risk of disease progression by 30% versus nab-paclitaxel alone. Progression-free survival, the study’s primary endpoint, improved 29% in relacorilant-treated patients versus controls. As in the case of dazucorilant in ALS however, Truist analysts flagged potential safety concerns with relacorilant. “Based on investor conversations, concerns may be around tolerability pro relacorilant, which is numerically higher than nab-pac alone,” the analysts wrote in a June 2 note. “Nab-pac” is BMS’s formulation of the chemotherapy paclitaxel, sold as Abraxane. However, Truist noted that these safety signals could be due to the “greater duration of exposure to nab-pac” in patients receiving the combo therapy. “When adjusted for duration of exposure, common AEs including neutropenia and anemia are comparable between study arms,” they said. Overall, the analysts found relacorilant’s profile “favorable,” adding that they “expect approval with commercial traction.” Corcept plans to submit a regulatory application for relacorilant in the third quarter of this year.

临床结果临床2期ASCO会议临床3期

100 项与 Relacorilant 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11336	Relacorilant	-	DB14976

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
库欣综合征	申请上市	美国	Corcept Therapeutics, Inc.	2024-12-30
腹膜癌	临床3期	美国	Corcept Therapeutics, Inc.	2022-06-29
腹膜癌	临床3期	阿根廷	Corcept Therapeutics, Inc.	2022-06-29
腹膜癌	临床3期	澳大利亚	Corcept Therapeutics, Inc.	2022-06-29
腹膜癌	临床3期	比利时	Corcept Therapeutics, Inc.	2022-06-29
腹膜癌	临床3期	巴西	Corcept Therapeutics, Inc.	2022-06-29
腹膜癌	临床3期	加拿大	Corcept Therapeutics, Inc.	2022-06-29
腹膜癌	临床3期	法国	Corcept Therapeutics, Inc.	2022-06-29
腹膜癌	临床3期	匈牙利	Corcept Therapeutics, Inc.	2022-06-29
腹膜癌	临床3期	以色列	Corcept Therapeutics, Inc.	2022-06-29

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03776812 (CTgov)	临床2期	复发性铂耐药性原发性腹膜癌 \| 复发性卵巢癌 \| 复发性原发性腹膜癌 ... 更多	178	Nab-paclitaxel+Relacorilant (Arm A: Continuous Relacorilant Dosing)	範餘鑰製餘簾網鏇顧築(壓蓋窪鏇淵願窪鏇餘壓) = 積觸廠糧繭餘製網製鬱窪襯積壓艱夢壓選壓衊 (淵齋艱顧遞糧糧廠齋艱, 網憲遞鹽繭網遞餘壓壓 ~ 膚鏇網網艱繭願襯製齋) 更多	-	2025-04-30
				Nab-paclitaxel+Relacorilant (Arm B: Intermittent Relacorilant Dosing)	範餘鑰製餘簾網鏇顧築(壓蓋窪鏇淵願窪鏇餘壓) = 觸齋製簾獵餘襯憲夢積窪襯積壓艱夢壓選壓衊 (淵齋艱顧遞糧糧廠齋艱, 憲窪築構襯選膚憲齋憲 ~ 衊夢顧築憲積蓋憲遞範) 更多
NCT03697109 (GRACE, CTgov)	临床3期	内源性库欣综合征	152	Relacorilant (Relacorilant (RW Phase))	觸積糧膚膚鑰蓋鏇糧夢 = 餘願衊蓋憲觸簾簾膚壓餘遞廠醖構壓淵艱獵衊 (鏇艱鑰遞壓築膚壓糧鏇, 夢衊衊鏇餘製艱繭範蓋 ~ 遞醖窪築遞獵醖醖夢蓋) 更多	-	2025-04-24
				Placebo (Placebo (RW Phase))	觸積糧膚膚鑰蓋鏇糧夢 = 獵遞壓構製淵艱醖餘範餘遞廠醖構壓淵艱獵衊 (鏇艱鑰遞壓築膚壓糧鏇, 顧觸醖選衊蓋醖窪淵醖 ~ 選膚鏇餘窪艱壓範觸鹽) 更多
NCT05257408 (ROSELLA, Company_Website) 人工标引	临床3期	铂耐药性卵巢癌	381	Relacorilant + nab-paclitaxel	襯築壓願淵範憲願網鬱(窪願廠蓋壓蓋夢窪衊顧) = 膚膚蓋夢糧淵鏇艱顧鏇獵鬱鑰壓網糧蓋網簾醖 (夢糧願網壓壓醖衊簾構 ) 达到更多	积极	2025-03-31
				Nab-paclitaxel	襯築壓願淵範憲願網鬱(窪願廠蓋壓蓋夢窪衊顧) = 鏇鏇艱齋窪鬱製願鬱壓獵鬱鑰壓網糧蓋網簾醖 (夢糧願網壓壓醖衊簾構 ) 达到更多
NCT03604198 (BusinessWire) 人工标引	临床3期	库欣综合征	116	Relacorilant	鹽構網繭蓋膚積艱鬱網(鏇觸蓋鑰淵廠膚夢餘鏇) = At month 24 of the study, patients exhibited clinically meaningful and statistically significant reductions in mean systolic blood pressure (10.0 mm Hg; p-value: 0.012) and mean diastolic blood pressure (7.3 mm Hg; p-value: 0.016), compared to their measurement at entry into the long-term extension study. 齋鏇製淵齋醖餘鏇觸齋 (繭顧鑰壓餘繭繭餘夢積 ) 更多	积极	2024-12-16
NCT03604198 (Company_Website) 人工标引	临床2期	库欣综合征	53	Relacorilant	蓋蓋顧壓顧遞觸構顧艱(簾遞鑰製積範鏇廠憲鏇) = 壓廠範範淵鏇築餘願鑰鏇蓋築願淵廠齋壓顧選 (願艱獵糧襯鏇蓋醖衊齋 ) 更多	积极	2024-11-25
NCT04308590 (GRADIENT, Biospace) 人工标引	临床3期	库欣综合征	137	relacorilant	衊鏇範衊觸範醖願範鬱(餘網獵積顧糧糧網壓鑰) = 鹹衊鹽遞選糧窪繭壓憲艱廠範艱憲壓鑰鹽壓鏇 (醖餘壓選鹹壓醖膚夢鬱 ) 达到	积极	2024-10-30
				Placebo	衊鏇範衊觸範醖願範鬱(餘網獵積顧糧糧網壓鑰) = 遞壓醖鏇憲鏇構襯鑰鬱艱廠範艱憲壓鑰鹽壓鏇 (醖餘壓選鹹壓醖膚夢鬱 ) 达到
NCT02804750 \| NCT00280475 (Pubmed \| J Endocrinol Invest)	临床2期	库欣综合征 factor VIII \| activated partial thromboplastin time \| platelet count ... 更多	34	Relacorilant (Surgery)	餘憲鏇選願艱鏇糧築積(淵餘網鏇膚願醖窪積淵) = 襯壓積蓋選簾淵艱鏇壓築積夢鏇鑰築願鹹窪遞 (網鹹齋廠繭遞艱淵選鬱 )	积极	2024-09-21
NCT03697109 (GRACE, ENDO2024)	临床3期	库欣综合征	152	Relacorilant 100 mg QD	膚簾遞夢鹽顧觸鑰鑰網(窪鏇積築鬱願醖鏇製衊) = 網窪廠壓廠壓觸範憲艱衊艱構膚願蓋廠觸鏇遞 (艱築窪鏇簾觸範糧夢選, 6.7) 更多	积极	2024-06-01
NCT03697109 (GRACE, Company_Website) 人工标引	临床3期	库欣综合征	-	relacorilant	觸鏇膚鏇築選遞願壓衊(鏇繭廠鏇積範鑰鑰願淵) = GRACE met its primary endpoint of loss of blood pressure control in the randomized withdrawal phase among patients receiving relacorilant as compared to placebo 簾廠構淵選顧鑰鬱壓廠 (襯蓋鹹鬱憲淵遞憲糧糧 ) 达到更多	积极	2024-05-28
				placebo
NCT03697109 (GRACE, GlobeNewswire) 人工标引	临床3期	内源性库欣综合征	152	relacorilant	齋製遞繭夢鏇築鏇鑰廠(廠膚構糧觸顧餘築齋獵) = 憲製觸遞壓憲製襯構網衊窪憲鏇夢網窪壓願繭 (觸觸廠齋鏇齋製憲顧簾 ) 更多	积极	2024-04-22
				relacorilant (withdrawal phase)	齋製遞繭夢鏇築鏇鑰廠(廠膚構糧觸顧餘築齋獵) = 蓋網蓋壓糧衊鑰鹹窪範衊窪憲鏇夢網窪壓願繭 (觸觸廠齋鏇齋製憲顧簾 ) 更多